common
circul
hcov
isol
children
hospit
acut
respiratori
tract
children
ambulatori
set
tabl
children
age
year
children
heart
diseas
frequent
reinfect
later
life
despit
fact
individu
seroconvert
hcov
contrast
respiratori
tract
virus
eg
respiratori
syncyti
viru
rsv
decreas
rel
preval
hcov
infect
increas
case
common
circul
hcov
found
coinfect
respiratori
virus
adeno
boca
rhino
rsv
influenza
parainfluenza
symptomat
children
whose
detect
respiratori
viru
hcov
report
like
suffer
underli
chronic
diseas
compar
children
coinfect
respiratori
common
circul
hcov
frequent
isol
cyclic
pattern
observ
outbreak
occur
everi
season
pattern
also
observ
northern
hemispher
common
circul
hcov
mostli
caus
infect
human
decemb
may
southern
hemispher
march
novemb
peak
late
winterearli
spring
autumn
report
mainli
occur
spring
summer
hong
winter
spring
unit
kingdom
sarscov
novel
group
betacoronaviru
initi
emerg
guangdong
provinc
south
china
spread
hong
kong
rapidli
mani
caus
sever
lower
respiratori
tract
infect
sever
morbid
high
casefat
rate
approach
individu
year
age
overal
persontoperson
transmiss
sarscov
well
viru
spread
countri
estim
caus
infect
death
worldwid
tabl
merscov
novel
group
betacoronaviru
first
appear
saudi
arabia
spread
caus
sever
lower
respiratori
tract
infect
casefat
rate
apart
endem
middl
east
nosocomi
outbreak
merscov
south
korea
involv
hospit
patient
caus
medic
doctor
return
middl
merscov
spread
countri
caus
estim
infect
death
tabl
overal
reproduct
number
sarscov
estim
merscov
tabl
larg
depend
geograph
locat
stage
outbreak
inclus
nosocomi
versu
gener
transmiss
virus
associ
earli
superspread
event
larg
number
secondari
infect
mostli
associ
nosocomi
outbreak
sarscov
case
mostli
health
care
worker
merscov
case
mostli
patient
occur
nosocomi
superspread
event
follow
reduc
spread
follow
gener
virus
decreas
merscov
tabl
therefor
sarscov
merscov
low
potenti
longterm
sustain
commun
transmiss
human
sarscov
infect
detect
sinc
juli
howev
sarscovlik
virus
found
bat
known
abl
infect
human
cell
without
adapt
make
possibl
sarscov
happen
zoonot
transmiss
merscov
human
continu
attribut
role
dromedari
camel
reservoir
close
contact
human
contrast
humanbatinteract
earli
outbreak
shown
persontoperson
transmiss
main
current
estim
incub
period
estim
day
similar
sarscov
serial
interv
estim
day
also
similar
novel
cov
tabl
march
world
health
organ
report
spread
countri
caus
infect
time
casefat
rate
uncertain
estim
much
lower
sarscov
merscov
respect
children
common
circul
hcov
caus
common
cold
symptom
also
case
gastrointestin
symptom
common
children
adult
studi
includ
children
adult
fatigu
headach
myalgia
sore
throat
common
hcovinfect
patient
compar
rsvinfect
patient
fever
cough
dyspnea
frequent
fewer
patient
infect
hcov
fever
compar
infect
rsv
children
associ
asthma
febril
febril
rare
case
neurolog
diseas
also
describ
eg
detect
hcov
cerebrospin
fluid
child
present
acut
dissemin
cerebrospin
fluid
adult
multipl
sclerosi
suspect
associ
hcov
kawasaki
diseas
could
common
hcov
isol
asymptomat
infect
viral
load
high
first
day
decreas
correl
viral
load
sever
diseas
contrast
sarscov
higher
initi
viral
load
independ
associ
wors
prognosi
includ
higher
casefat
viru
particl
isol
nasopharyng
secret
day
onset
case
seri
report
total
children
affect
viru
associ
milder
diseas
children
compar
adult
death
report
symptomat
children
sarscov
infect
report
fever
myalgia
rhiniti
sore
throat
cough
dyspnea
headach
less
commonli
vomit
abdomin
pain
diarrhea
febril
seizur
total
children
famili
member
nosocomi
contact
children
recov
quickli
infect
howev
abnorm
chest
comput
tomographi
ct
persist
sever
month
eg
air
trap
groundglass
opacif
evid
sarscov
vertic
transmit
howev
sarscov
infect
pregnanc
associ
possibl
miscarriag
intrauterin
growth
retard
preterm
case
seri
patient
infect
merscov
report
low
proport
larg
case
seri
children
acut
respiratori
tract
infect
present
tertiari
hospit
saudi
arabia
merscov
epidem
none
test
posit
merscov
tabl
small
case
seri
children
infect
merscov
one
includ
children
mean
age
one
studi
children
case
seri
children
suffer
fever
vomit
diarrhea
cough
short
two
children
requir
oxygen
supplement
one
mechan
case
seri
die
main
sourc
merscov
infect
children
household
contact
follow
nosocomi
transmiss
eight
case
merscov
matern
infect
pregnanc
report
occur
week
pregnanc
three
affect
infant
differ
case
definit
case
adult
children
authorit
sourc
march
detail
tabl
children
less
commonli
affect
chines
center
diseas
control
prevent
report
case
report
februari
individu
less
year
case
seri
children
infect
first
includ
children
januari
provinc
second
children
januari
februari
provinc
third
infant
differ
provinc
case
seri
children
provid
clinic
detail
none
children
underli
diseas
common
respiratori
symptom
mild
diseas
common
symptom
fever
cough
case
seri
children
present
low
moder
fever
rhiniti
cough
fatigu
headach
diarrhea
sever
case
dyspnea
cyanosi
poor
feed
number
seri
infant
report
fever
one
infant
addit
asymptomat
children
infect
outsid
case
seri
also
describ
eg
asymptomat
child
radiolog
groundglass
lung
opac
chest
ct
infect
children
recov
week
onset
symptom
death
report
februari
seri
appear
children
milder
clinic
symptom
report
sarscov
merscov
infect
could
mean
children
might
test
frequent
adult
therefor
suggest
asymptomat
mildli
symptomat
children
might
transmit
howev
major
children
infect
thu
far
part
famili
cluster
outbreak
infant
seri
famili
member
symptom
infant
case
case
seri
children
major
one
children
exact
number
specifi
similar
sarscov
children
report
affect
household
merscov
studi
prepublish
earli
march
suggest
children
like
adult
becom
infect
less
like
symptomat
develop
sever
howev
import
children
transmit
viru
remain
uncertain
small
case
seri
mother
infect
date
evid
vertic
transmit
laboratori
find
observ
children
infect
case
seri
children
white
blood
cell
count
normal
neutropenia
lymphopenia
found
case
lactat
dehydrogenas
level
elev
creactiv
protein
procalcitonin
level
elev
case
ct
chang
observ
children
infect
includ
bilater
multipl
patchi
nodular
groundglass
opac
speckl
groundglass
opac
andor
infiltr
shadow
middl
outer
zone
lung
find
unspecif
milder
compar
whole
genom
sequenc
allow
rapid
develop
molecular
diagnost
test
rtpcr
gene
encod
intern
rnadepend
rna
polymeras
surfac
spike
glycoprotein
commonli
absenc
specif
antivir
drug
cov
broadspectrum
antivir
drug
interferon
alpha
beta
ribavirin
use
treatment
sarscov
includ
ribavirin
subsequ
shown
ineffect
even
harm
caus
hemolyt
anemia
liver
adult
interferonalpha
alon
togeth
ribavirin
also
consist
improv
evid
intraven
corticosteroid
led
clinic
radiolog
improv
sarscovinfect
howev
systemat
review
show
evid
inconclus
corticosteroid
might
also
harm
delay
viral
clearanc
avascular
necrosi
osteoporosi
new
onset
diabet
evid
adult
studi
lopinavirritonavir
kaletra
start
earli
infect
associ
improv
clinic
outcom
decreas
intub
ard
death
rate
howev
systemat
review
found
inconclus
result
use
lopinavirritonavir
possibl
select
bia
mani
inconclus
result
also
found
intraven
immunoglobulin
studi
account
comorbid
stage
ill
effect
evid
use
monoclon
antibodi
tumor
necrosi
factor
studi
treatment
outcom
merscov
children
adult
sarscov
interferon
ribavirin
alon
combin
shown
clear
mycophenol
mofetil
inhibit
guanin
therefor
rna
synthesi
identifi
potenti
antimerscov
drug
howev
anim
studi
show
drug
lead
wors
outcom
higher
viral
load
lung
extrapulmonari
consist
renal
transplant
patient
mycophenol
mofetil
report
develop
sever
sometim
fatal
merscov
result
ongo
clinic
trial
becom
avail
definit
evid
base
treatment
patient
infect
treatment
recommend
children
publish
zhejiang
univers
school
medicin
suggest
use
nebul
interferon
oral
lopinavirritonavir
togeth
corticosteroid
complic
ard
enceph
hemophagocyt
syndrom
septic
shock
intraven
immunoglobulin
sever
howev
none
therapi
shown
clear
benefit
treatment
novel
cov
question
whether
benefici
treatment
neither
world
health
organ
us
center
diseas
control
prevent
recommend
specif
treatment
children
despit
previous
mention
case
seri
children
infect
treat
none
children
receiv
glucocorticoid
despit
divers
cov
share
mani
protein
among
differ
speci
help
design
new
drug
one
surfac
structur
spike
glycoprotein
respons
viruscel
monoclon
antibodi
convalesc
human
plasma
anim
plasma
manufactur
spike
glycoprotein
shown
inhibit
fusion
cov
human
cell
decreas
mortal
rate
sarscovinfect
protein
also
inhibit
spike
glycoprotein
although
monoclon
antibodi
isol
red
alga
call
howev
date
test
anim
angiotensinconvert
enzym
dipeptidyl
peptidas
aminopeptidas
n
oacetyl
sialic
acid
host
receptor
hcov
monoclon
antibodi
protein
might
use
treatment
howev
rapid
mutat
cov
pose
potenti
problem
might
diminish
use
sever
monoclon
antibodi
target
differ
chloroquin
commonli
use
malaria
autoimmun
diseas
increas
endosom
ph
therebi
inhibit
viruscel
fusion
therefor
potenti
broadspectrum
antivir
also
interfer
glycosyl
cellular
receptor
addit
vitro
studi
show
chloroquin
inhibit
entri
postentri
stage
moreov
chloroquin
possess
immunemodul
activ
might
enhanc
antivir
effect
previous
mention
ribavirin
guanosin
analog
shown
ineffect
even
harm
immucillina
new
adenosin
analog
recent
develop
inhibit
viral
rna
polymeras
wide
rang
rna
virus
includ
sarscov
might
use
treatment
hcov
furthermor
inhibitor
helicas
protein
unwind
doublestrand
rna
singl
strand
replic
might
use
treatment
rna
synthesi
inhibitor
reduc
format
doublemembran
vesicl
hallmark
replic
identifi
potenti
antivir
doublestrand
rna
activ
caspas
oligomer
draco
target
long
viral
doublestrand
rna
induc
apoptosi
infect
cell
spare
healthi
cell
might
also
use
treatment
advantag
liveattenu
vaccin
usual
induc
robust
longlast
immun
respons
includ
cellular
humor
immun
mani
differ
antigen
sarscov
anim
studi
attenu
mutant
delet
structur
e
gene
shown
induc
neutral
antibodi
reduc
viral
load
protect
clinic
symptom
sarscov
contrast
delet
open
read
frame
littl
effect
viral
load
vitro
strategi
develop
liveattenu
vaccin
cov
genom
rearrang
gene
advantag
vaccin
viru
recombin
wild
virus
mous
model
inactiv
vaccin
success
induc
cellular
humor
immun
mani
differ
neutral
antibodi
humor
immun
human
phase
trial
inactiv
vaccin
sarscov
well
toler
elicit
neutral
howev
challeng
studi
done
human
monkey
challeng
studi
clear
evid
protect
shown
despit
induct
strong
cellular
humor
moreov
concern
rais
inactiv
vaccin
sarscov
merscov
may
lead
harm
immun
andor
inflammatori
respons
subunit
vaccin
purifi
antigen
usual
combin
adjuv
popular
method
develop
vaccin
novel
cov
sarscov
merscov
mostli
develop
spike
glycoprotein
rbd
nucleocapsid
studi
show
subunit
vaccin
given
intranas
might
induc
stronger
immun
respons
mucos
sever
subunit
vaccin
shown
success
anim
challeng
studi
monkey
recombin
rbd
protein
use
success
reduc
viral
load
lung
oropharynx
prevent
merscov
mice
similar
result
achiev
use
recombin
rbd
protein
vaccin
adenovirusbas
vector
encod
sar
protein
eg
nucleocapsid
protein
spike
glycoprotein
membran
protein
shown
immunogen
mice
rhesu
macaqu
induc
humor
cellular
vaccin
adenovirusbas
vaccin
carri
part
merscov
shown
reduc
morbid
mortal
undetect
reduc
pulmonari
viral
load
mous
initi
pulmonari
hemorrhag
observ
postvir
howev
ad
ligand
vaccin
enhanc
immunogen
efficaci
also
prevent
inadvert
pulmonari
patholog
make
vaccin
promis
nonetheless
preexist
immun
adenoviru
might
reduc
efficaci
might
address
give
viralbas
vaccin
follow
recombin
vaccin
adenovirusbas
merscov
vaccin
move
phase
clinic
one
studi
compar
inactiv
sarscov
vaccin
adenovirusbas
vaccin
sarscov
found
first
led
higher
humor
adenovirusbas
vaccin
administ
intranas
led
immunoglobulin
antibodi
product
associ
superior
protect
viru
replic
indic
measur
serum
neutral
antibodi
might
suffici
way
assess
vaccin
efficaci
hcov
mucos
immun
might
import
sarscov
poxviru
also
use
vector
intranas
intramuscularli
administ
vaccin
vaccineinduc
neutral
antibodi
reduc
viral
load
respiratori
tract
challeng
howev
similar
vaccin
use
ferret
led
increas
liver
damag
sarscov
vector
vaccin
sarscov
test
anim
base
recombin
parainfluenza
liveattenu
recombin
measl
attenu
rabi
attenu
vaccin
contain
dna
encod
spike
glycoprotein
seem
induc
robust
respons
neutral
antibodi
merscov
vaccin
contain
rbd
protein
shown
protect
rhesu
macaqu
merscov
three
dna
vaccin
merscov
advanc
clinic
quickli
spread
across
globe
sarscov
contain
highli
effect
global
public
health
respons
highlight
urgent
need
rapid
effect
strategi
infect
control
one
main
challeng
novel
cov
high
potenti
nosocomi
health
care
set
seem
increas
risk
viral
transmiss
due
aerosolgener
procedur
intub
bronchoscopi
appropri
hospit
hygien
practic
therefor
crucial
limit
nosocomi
outbreak
main
aim
effect
triag
patient
fever
respiratori
symptom
contact
appli
stringent
infect
control
measur
isol
patient
quarantin
contact
earli
possibl
ideal
patient
place
singl
neg
pressur
room
possibl
patient
health
care
worker
protect
gear
includ
waterresist
gown
dispos
glove
mask
goggl
face
suction
cathet
mechan
respir
closedcircuit
system
viral
filter
contrast
nebul
oxygen
mask
nasal
continu
posit
airway
pressur
system
use
open
needless
say
strict
hand
hygien
need
appli
visitor
avoid
limit
absolut
minimum
hcov
shown
persist
dri
surfac
persist
depend
temperatur
shorter
durat
humid
longer
higher
humid
hcov
includ
novel
cov
inactiv
heat
minut
use
lipid
solvent
ethanol
isopropanol
formaldehyd
povidoneiodin
sodium
hypochlorit
hydrogen
peroxid
sarscov
merscov
infect
seem
affect
children
less
commonli
less
sever
compar
adult
might
children
less
frequent
expos
main
sourc
transmiss
disproport
nosocomi
less
expos
anim
howev
could
also
children
less
frequent
symptomat
less
sever
symptom
therefor
less
often
test
lead
underestim
true
number
infect
relat
studi
prepublish
earli
march
suggest
children
like
adult
becom
infect
viru
less
like
symptomat
develop
sever
howev
import
children
transmit
viru
remain
uncertain
major
children
infect
novel
cov
report
thu
far
document
household
contact
often
show
symptom
suggest
possibl
children
import
reservoir
novel
cov
clinic
laboratori
radiolog
featur
children
similar
novel
cov
except
children
infect
sarscov
present
fever
compar
merscov
date
death
children
report
sarscov
except
case
former
infant
mother
infect
pregnanc
